Meredith Nelson handles a broad range of complex litigation matters in federal and state courts, including representing plaintiffs and defendants in contract and earnout disputes, bankruptcy-related disputes, and industry-specific matters in the healthcare, financial services, and insurance sectors.
Prior to joining Selendy Gay, Meredith served as a law clerk to the Honorable Gregory H. Woods for the U.S. District Court for the Southern District of New York. She earned her J.D. from New York University School of Law, where she was an Executive Editor of the New York University Law Review.
Meredith was named to Best Lawyers 2026 and 2027 “Ones to Watch in America” list, which recognizes rising legal talent across the nation for excellence in their respective fields. She was also named to Super Lawyers' 2026 "Rising Stars" list in the publication's general commercial category.
Meredith’s representations include:
- Fortis Advisors: Represented the former shareholders of Auris Health, a revolutionary robotic surgery startup, in a merger earnout dispute with its acquiror, Johnson & Johnson. The former shareholders alleged that J&J breached the merger agreement and defrauded the shareholders, resulting in its failure to achieve certain earnout milestones. After four years of litigation—including approximately 70 depositions, nine experts, and a 10-day trial in the Delaware Court of Chancery—Selendy Gay obtained the largest earnout-related damages award in the history of Delaware. The team successfully defended the victory on appeal in the Delaware Supreme Court, upholding the trial court’s contract and fraud holdings and securing a final $811 million damages award against J&J.
- Albertsons, in a merger dispute against Kroger in the Delaware Court of Chancery, alleging that Kroger materially breached the merger agreement by failing to undertake efforts required under the specific terms of the agreement to secure regulatory approval and, additionally, by failing to pay the termination fee. Albertsons seeks damages in excess of $6 billion.
- SaveOnSP, in a lawsuit brought by Johnson & Johnson Health Care Systems Inc. for tortious interference with contract and deceptive trade practices. This lawsuit will have an industry-wide impact on the ability of commercial health plans to set plan terms that counteract the deleterious effects of drug manufacturers’ copay assistance programs.
- SaveOn SP, in defending against a putative class action claiming hundreds of millions in damages for alleged violations of RICO and ERISA.
- Bayer, in a complaint against Janssen Pharmaceuticals (a division of Johnson & Johnson) arising from J&J’s decision to scale back and ultimately terminate in-person promotion (a practice known as “detailing”) for the drug Xarelto. Bayer alleges that J&J breached the parties’ contract, under which Bayer granted J&J an exclusive license to sell Xarelto in the United States in exchange for J&J’s commitment to use commercially reasonable efforts to market the product, including detailing. In August 2026, the court denied J&J’s motion to dismiss in its entirety, allowing Bayer’s claims for lost royalties to proceed to discovery.
- UMB Bank as Trustee for holders of Celgene contingent value rights, seeking nearly $7 billion in damages arising from Bristol Myers Squibb’s failure to timely secure regulatory approval of the cancer therapies associated with the CVR payout.
- KRyS Global, a British Virgin Islands-based foreign representative of several funds in liquidation abroad, in Chapter 15 proceedings in Bankruptcy Court for the Southern District of New York, and before the U.S. District Court on appeal, asserting foreign avoidance, common law, and breach of contract claims, seeking to recover approximately $6 billion in redemption payments from hundreds of entities arising out of the Madoff scheme.
-
Selendy Gay Secures Denial of Johnson & Johnson’s Motion to Dismiss in Contract Dispute
Selendy Gay secured a victory for Bayer in its contractual dispute against Johnson & Johnson over Johnson & Johnson’s promotion of the blood thinner Xarelto in the U.S. On August 4, Judge Dale E. Ho of the U.S. District Court for the Southern District of New York denied Johnson & Johnson’s motion to dismiss in its entirety, concluding that the lost royalties Bayer seeks constitute general damages and that the parties’ agreement does not plainly preclude their recovery.
-
-
-
Selendy Gay Secures $1.1 Billion Trial Victory Against Johnson & Johnson
Selendy Gay and Delaware co-counsel Ross Aronstam & Moritz secured a very significant trial victory on behalf of the former stockholders of Auris Health, Inc (represented by Fortis Advisors) in their long-running earnout dispute with Johnson & Johnson. Following a January trial, Vice Chancellor Lori W. Will of the Delaware Court of Chancery issued a decision awarding more than $1 billion in damages for J&J’s breach of contract, breach of implied covenant, and fraud. The 145-page decision constitutes the most important precedent and largest award in Delaware history in an earnout case.
-
-
Selendy Gay Ranked Among the Nation's Leading Litigation Firms in Legal 500 U.S. 2026
Selendy Gay has once again been recognized by Legal 500 U.S. among the nation’s leading litigation firms, earning rankings across four practice areas in the 2026 guide.
The firm maintained its Tier 3 rankings in General Commercial Disputes – Premium ($500M+), M&A Litigation: Plaintiff, and Securities Litigation: Plaintiff. In addition, Selendy Gay earned a new ranking in Restructuring (Including Bankruptcy): Corporate.
-
-
-
-
-
Best Practices for AI in Litigation
We are several years into the arms race among tech incumbents and upstarts to develop new artificial intelligence applications. Many of the new tools are marketed directly to litigators, promising to make dispute resolution more efficient and less expensive. Selendy Gay tasked a dedicated team of lawyers and other legal professionals with testing litigation-specific applications of AI.